

VitaSIR0 soloTM

MT-RNR1 SNP Assay CE IVD

A Single Nucleotide Polymorphism (SNP) in the MT-RNR1 gene, specifically m.1555A>G, is the primary cause of Aminoglycoside-Induced Hearing Loss (AIHL). This mutation can result in ototoxicity when patients receive aminoglycoside antibiotics, which are essential for treating infections, particularly in infants.

Current diagnostic methods for detecting these mutations are limited. To enhance patient safety, Credo Diagnostics Biomedical has developed the MT-RNR1 SNP Assay, delivering results in just 20 minutes. This rapid turnaround allows for timely interventions to prevent hearing loss.



Non-Invasive Sampling

Easier and faster buccal swab specimen collection



Easy Storage and Rapid Results

< 1-minute hands-on time and 20-minute turnaround time, with storage at room temperature



Precision Diagnostics

High sensitivity and specificity

Diagnostic Procedure in 4 Steps:



Collect





Lyse



Transfer



Start Run



Note:

- (1). The MT-RNR1 SNP Assay is validated with EMQN MT-RNR1 POCT Device Verification Sample, and we diluted the known sample by 10-fold to simulate 100 cell per swab.
- (2). Wild type gene, m.1555A is not detected in all above tests.

Credo Diagnostics Biomedical Pte. Ltd.

491B River Valley Road #06-01 Valley Point Singapore 248373

✉ service@credodxbiomed.com

🌐 credodxbiomed.com

Version: v3.0 January 2026